Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent
antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L
braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This
trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis
in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony.
Standard dose regimens will be used for both drugs.